WebbAchilles Therapeutics plc (ACHL) Stock Price, News, Quote & History - Yahoo Finance My Portfolio (-0.30%) Achilles Therapeutics plc (ACHL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD... WebbOur Pipeline Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. We are also pursuing …
Rare Oncology Treatment Pipeline - SpringWorks Therapeutics
WebbIn 2024, the company underwent a strategic transformation to focus on our innovative therapeutics pipeline, and in 2024 we became Biora Therapeutics, Inc. We are currently focused on developing therapeutics technologies that improve patients’ lives, through a revolutionary combination of drug therapies and smart capsule technology. WebbPipeline Autolus Treating hematological malignancies and solid tumors The company’s lead therapeutic candidate, obe-cel, met its primary endpoint at an interim analysis of the pivotal phase 2 FELIX study for adult ALL. Additional data is expected in mid-2024 with a BLA submission to the US FDA planned by the end of 2024. directory synchronization 130
Pipeline Achilles Therapeutics
Webbachilles pipeline Our lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Our lead indications, advanced non-small cell lung cancer … Webb11 apr. 2024 · Design Therapeutics has been unprofitable, quarter after quarter. This makes it difficult to properly value the company and its stock, as Design Therapeutics has no price-to-earnings (P/E) ratio ... Webbför 12 timmar sedan · SpringWorks Therapeutics, Inc.'s key catalyst right now is the PDUFA, and the underlying trial was by all reports a success. However, if you look at the … directory synchronization イベントログ